Skip to main content

Advertisement

SpringerLink
Log in

PTH level might be associated with impaired quality of life in patients with nonsurgical hypoparathyroidism

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Objective

Nonsurgical hypoparathyroidism (ns-HP) is a rare disease. There are few studies on Quality of Life (QoL) among patients with ns-HP. This study aimed to investigate the QoL among ns-HP patients with regular conventional treatment, and explore the influence factors affecting QoL among these Chinese ns-HP patients.

Methods

This is a cross-sectional study comparing 101 patients identified as ns-HP and 101 healthy controls. The questionnaires of Short Form 36 Health Survey questionnaire version 2(SF-36v2) were used to evaluate QoL.

Results

Scores of all eight subdomains of SF-36v2 and physical component scores (PCS), mental component scores (MCS) were significantly lower in the ns-HP group compared with the healthy controls. The indices of all subdomains of SF-36v2 between Q1 (the lowest quartile) and Q4 (the highest quartile) groups were compared, suggesting higher percentages of detectable parathyroid hormone (PTH) before treatment in Q4 group among all QoL indices except two subdomains (physical function and body pain).

Conclusion

Both mental and physical QoL were impaired in the ns-HP patients even with regular conventional treatment for hypocalcemia, which were more severe in cases with lower baseline PTH levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

References

  1. Underbjerg L, Sikjaer T, Mosekilde L et al (2015) The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study. J Bone Miner Res 30:1738–1744

    Article  CAS  PubMed  Google Scholar 

  2. Nakamura Y, Matsumoto T, Tamakoshi A et al (2000) Prevalence of idiopathic hypoparathyroidism and pseudohypoparathyroidism in Japan. J Epidemiol 10:29–33

    Article  CAS  PubMed  Google Scholar 

  3. Halabe A, Arie R, Mimran D et al (1994) Hypoparathyroidism–a long-term follow-up experience with 1 alpha-vitamin D3 therapy. Clin Endocrinol (Oxf) 40:303–307

    Article  CAS  PubMed  Google Scholar 

  4. Cooper MS, Gittoes NJ (2008) Diagnosis and management of hypocalcaemia. BMJ 336:1298–1302

    Article  PubMed  PubMed Central  Google Scholar 

  5. Denko JD, Kaelbling R (1962) The psychiatric aspects of hypoparathyroidism. Acta Psychiatr Scand Suppl 38:1–70

    CAS  PubMed  Google Scholar 

  6. Arlt W, Fremerey C, Callies F et al (2002) Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol 146:215–222

    Article  CAS  PubMed  Google Scholar 

  7. Buttner M, Musholt TJ, Singer S (2017) Quality of life in patients with hypoparathyroidism receiving standard treatment: a systematic review. Endocrine 58:14–20

    Article  PubMed  Google Scholar 

  8. Palermo A, Santonati A, Tabacco G et al (2018) PTH (1–34) for surgical hypoparathyroidism: a 2-year prospective, open-label investigation of efficacy and quality of life. J Clin Endocrinol Metab 103:271–280

    Article  PubMed  Google Scholar 

  9. Cusano NE, Rubin MR, McMahon DJ et al (2013) The effect of PTH (1–84) on quality of life in hypoparathyroidism. J Clin Endocrinol Metab 98:2356–2361

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Cusano NE, Rubin MR, McMahon DJ et al (2014) PTH (1–84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. J Clin Endocrinol Metab 99:3694–3699

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Santonati A, Palermo A, Maddaloni E et al (2015) PTH (1–34) for surgical hypoparathyroidism: a prospective, open-label investigation of efficacy and quality of life. J Clin Endocrinol Metab 100:3590–3597

    Article  CAS  PubMed  Google Scholar 

  12. Tabacco G, Tay YD, Cusano NE et al (2019) Quality of Life in hypoparathyroidism improves with rhPTH (1–84) throughout 8 Years of therapy. J Clin Endocrinol Metab 104:2748–2756

    Article  PubMed  PubMed Central  Google Scholar 

  13. Sikjaer T, Rolighed L, Hess A et al (2014) Effects of PTH(1–84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos Int 25:1717–1726

    Article  CAS  PubMed  Google Scholar 

  14. Roszko KL, Hu TY, Guthrie LC et al (2022) PTH 1–34 replacement therapy has minimal effect on quality of life in patients with hypoparathyroidism. J Bone Miner Res 37:68–77

    Article  CAS  PubMed  Google Scholar 

  15. Gittoes N, Rejnmark L, Ing SW et al (2021) The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics. BMC Endocr Disord 21:232

    Article  PubMed  PubMed Central  Google Scholar 

  16. Kumanishi T, Washiyama K, Saito T et al (1986) Primary malignant lymphoma of the brain: an immunohistochemical study of eight cases using a panel of monoclonal and heterologous antibodies. Acta Neuropathol 71:190–196

    Article  CAS  PubMed  Google Scholar 

  17. Jorgensen CU, Homoe P, Dahl M et al (2021) Postoperative chronic hypoparathyroidism and quality of life after total thyroidectomy. JBMR Plus 5:e10479

    Article  PubMed  PubMed Central  Google Scholar 

  18. Sikjaer T, Moser E, Rolighed L et al (2016) Concurrent hypoparathyroidism is associated with impaired physical function and quality of life in hypothyroidism. J Bone Miner Res 31:1440–1448

    Article  PubMed  Google Scholar 

  19. Astor MC, Lovas K, Debowska A et al (2016) Epidemiology and health-related quality of life in hypoparathyroidism in norway. J Clin Endocrinol Metab 101:3045–3053

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Underbjerg L, Sikjaer T, Rejnmark L (2018) Health-related quality of life in patients with nonsurgical hypoparathyroidism and pseudohypoparathyroidism. Clin Endocrinol (Oxf) 88:838–847

    Article  CAS  PubMed  Google Scholar 

  21. Aggarwal S, Kailash S, Sagar R et al (2013) Neuropsychological dysfunction in idiopathic hypoparathyroidism and its relationship with intracranial calcification and serum total calcium. Eur J Endocrinol 168:895–903

    Article  CAS  PubMed  Google Scholar 

  22. Sardella A, Bellone F, Morabito N et al (2021) The association between hypoparathyroidism and cognitive impairment: a systematic review. J Endocrinol Invest 44:905–919

    Article  CAS  PubMed  Google Scholar 

  23. Saponaro F, Alfi G, Cetani F et al (2022) Serum calcium levels are associated with cognitive function in hypoparathyroidism: a neuropsychological and biochemical study in an Italian cohort of patients with chronic post-surgical hypoparathyroidism. J Endocrinol Invest 45:1909–1918

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Bonavolontà V, Cianferotti L, Iolascon G et al (2022) Which physical activity in patients affected by hypoparathyroidism? A review of the literature and practical recommendations. J Endocrinol Invest 45:1289–1295

    Article  PubMed  Google Scholar 

  25. Balabanov S, Tollner U, Richter HP et al (1984) Immunoreactive parathyroid hormone, calcium, and magnesium in human cerebrospinal fluid. Acta Endocrinol (Copenh) 106:227–233

    CAS  PubMed  Google Scholar 

  26. Usdin TB, Gruber C, Bonner TI (1995) Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor. J Biol Chem 270:15455–15458

    Article  CAS  PubMed  Google Scholar 

  27. Bago AG, Dimitrov E, Saunders R et al (2009) Parathyroid hormone 2 receptor and its endogenous ligand tuberoinfundibular peptide of 39 residues are concentrated in endocrine, viscerosensory and auditory brain regions in macaque and human. Neuroscience 162:128–147

    Article  CAS  PubMed  Google Scholar 

  28. Vokes TJ, Mannstadt M, Levine MA et al (2018) Recombinant human parathyroid hormone effect on health-related quality of life in adults with chronic hypoparathyroidism. J Clin Endocrinol Metab 103:722–731

    Article  PubMed  Google Scholar 

  29. Chomsky-Higgins KH, Rochefort HM, Seib CD et al (2018) Recombinant parathyroid hormone versus usual care: do the outcomes justify the cost? World J Surg 42:431–436

    Article  PubMed  Google Scholar 

Download references

Funding

This work was supported by the National Natural Science Foundation of China (No. 82070817).

Author information

Authors and Affiliations

  1. Department of Endocrinology, Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan Wangfujing, Beijing, 100730, China

    A. Song, S. Chen, Y. Yang, Y. Jiang, Y. Jiang, M. Li, W. Xia, O. Wang & X. Xing

Authors
  1. A. Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y. Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y. Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W. Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. O. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. X. Xing
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to O. Wang or X. Xing.

Ethics declarations

Conflict of interest

The authors declare no confict of interest.

Ethical approval

This study was conducted in accordance with the principles of the Declaration of Helsinki and approved by the Ethics Committee of PUMCH (ZS-1689).

Informed consent

Each patient signed the informed consent document before the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Song, A., Chen, S., Yang, Y. et al. PTH level might be associated with impaired quality of life in patients with nonsurgical hypoparathyroidism. J Endocrinol Invest 46, 2471–2479 (2023). https://doi.org/10.1007/s40618-023-02100-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-023-02100-9

Keywords

Search

Navigation